PD-L1单抗-话题@MedSci

#PD-L1单抗#

49篇内容 | 2594人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1538958, encodeId=a718153895848, content=<a href='/topic/show?id=349913924d1' target=_blank style='color:#2F92EE;'>#PD-L1单抗#</a>, objectTitle=NICE推荐将罗氏的PD-L1单抗Tecentriq，用于治疗转移性非小细胞肺癌, objectType=article, longId=165339, objectId=4a3216533980, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4a3216533980, replyNumber=0, likeNumber=88, createdTime=2019-05-05, rootId=0, userName=ylz8407, userId=195c13086613, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4a3216533980, moduleTitle=NICE推荐将罗氏的PD-L1单抗Tecentriq，用于治疗转移性非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4a3216533980)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1538957, encodeId=040d153895e0f, content=<a href='/topic/show?id=349913924d1' target=_blank style='color:#2F92EE;'>#PD-L1单抗#</a>, objectTitle=Maxinovel的口服PD-L1抑制剂被证明与PD-L1单抗Durvalumab有相似活性, objectType=article, longId=164834, objectId=5f4516483459, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5f4516483459, replyNumber=0, likeNumber=58, createdTime=2019-04-24, rootId=0, userName=ylz8407, userId=195c13086613, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5f4516483459, moduleTitle=Maxinovel的口服PD-L1抑制剂被证明与PD-L1单抗Durvalumab有相似活性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5f4516483459)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1538956, encodeId=7582153895668, content=<a href='/topic/show?id=349913924d1' target=_blank style='color:#2F92EE;'>#PD-L1单抗#</a>, objectTitle=罗氏的AKT抑制剂ipatasertib联合PD-L1单抗和紫杉醇，显示出对三阴性乳腺癌的治疗前景, objectType=article, longId=163592, objectId=c75b163592a1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c75b163592a1, replyNumber=0, likeNumber=0, createdTime=2019-04-05, rootId=0, userName=ylz8407, userId=195c13086613, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c75b163592a1, moduleTitle=罗氏的AKT抑制剂ipatasertib联合PD-L1单抗和紫杉醇，显示出对三阴性乳腺癌的治疗前景, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c75b163592a1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1538955, encodeId=51c01538955fd, content=<a href='/topic/show?id=349913924d1' target=_blank style='color:#2F92EE;'>#PD-L1单抗#</a>, objectTitle=罗氏的PD-L1单抗Tecentriq 治疗三阴性乳腺癌即将获得FDA批准, objectType=article, longId=162148, objectId=423a1621482c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=423a1621482c, replyNumber=0, likeNumber=81, createdTime=2019-03-13, rootId=0, userName=ylz8407, userId=195c13086613, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=423a1621482c, moduleTitle=罗氏的PD-L1单抗Tecentriq 治疗三阴性乳腺癌即将获得FDA批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=423a1621482c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1538954, encodeId=12dc1538954fc, content=<a href='/topic/show?id=349913924d1' target=_blank style='color:#2F92EE;'>#PD-L1单抗#</a>, objectTitle=欧洲药品管理局验证了默克PD-L1单抗Bavencio在晚期肾细胞癌中的疗效, objectType=article, longId=161940, objectId=45871619401a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=45871619401a, replyNumber=0, likeNumber=79, createdTime=2019-03-10, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=45871619401a, moduleTitle=欧洲药品管理局验证了默克PD-L1单抗Bavencio在晚期肾细胞癌中的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=45871619401a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1538953, encodeId=384a153895353, content=<a href='/topic/show?id=349913924d1' target=_blank style='color:#2F92EE;'>#PD-L1单抗#</a>, objectTitle=阿斯利康的PD-L1单抗Imfinzi欧洲获批用于治疗局部晚期且不可切除的非小细胞肺癌, objectType=article, longId=149623, objectId=297e149623e6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=297e149623e6, replyNumber=0, likeNumber=61, createdTime=2018-09-27, rootId=0, userName=ylz8407, userId=195c13086613, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=297e149623e6, moduleTitle=阿斯利康的PD-L1单抗Imfinzi欧洲获批用于治疗局部晚期且不可切除的非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=297e149623e6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1538952, encodeId=9037153895277, content=<a href='/topic/show?id=349913924d1' target=_blank style='color:#2F92EE;'>#PD-L1单抗#</a>, objectTitle=康宁杰瑞与思路迪联合开发的PD-L1单抗获国家食药总局临床批件, objectType=article, longId=86908, objectId=4ca38690865, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4ca38690865, replyNumber=0, likeNumber=0, createdTime=2017-01-08, rootId=0, userName=ylz8407, userId=195c13086613, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4ca38690865, moduleTitle=康宁杰瑞与思路迪联合开发的PD-L1单抗获国家食药总局临床批件, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4ca38690865)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1538951, encodeId=f4e81538951b3, content=<a href='/topic/show?id=349913924d1' target=_blank style='color:#2F92EE;'>#PD-L1单抗#</a>, objectTitle=罗氏的PD-L1单抗获优先审评权，有望今年9月获批上市, objectType=article, longId=65151, objectId=432f65151fc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=432f65151fc, replyNumber=0, likeNumber=56, createdTime=2016-03-23, rootId=0, userName=ylz8407, userId=195c13086613, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=432f65151fc, moduleTitle=罗氏的PD-L1单抗获优先审评权，有望今年9月获批上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=432f65151fc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1538950, encodeId=affd1538950d9, content=<a href='/topic/show?id=349913924d1' target=_blank style='color:#2F92EE;'>#PD-L1单抗#</a>, objectTitle=Lancet：PD-L1单抗Atezolizumab治疗转移性尿路上皮癌活性和耐受性良好, objectType=article, longId=64211, objectId=be266421184, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=be266421184, replyNumber=0, likeNumber=86, createdTime=2016-03-08, rootId=0, userName=ylz8407, userId=195c13086613, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=be266421184, moduleTitle=Lancet：PD-L1单抗Atezolizumab治疗转移性尿路上皮癌活性和耐受性良好, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=be266421184)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

PD-L1单抗

2020-05-29

ylz8407 (审核中...)

前往app查看评论内容

#PD-L1单抗#

NICE推荐将罗氏的PD-L1单抗Tecentriq，用于治疗转移性非小细胞肺癌

2019-05-05

ylz8407 (审核中...)

前往app查看评论内容

#PD-L1单抗#

Maxinovel的口服PD-L1抑制剂被证明与PD-L1单抗Durvalumab有相似活性

2019-04-24

ylz8407 (审核中...)

前往app查看评论内容

#PD-L1单抗#

罗氏的AKT抑制剂ipatasertib联合PD-L1单抗和紫杉醇，显示出对三阴性乳腺癌的治疗前景

2019-04-05

ylz8407 (审核中...)

前往app查看评论内容

#PD-L1单抗#

罗氏的PD-L1单抗Tecentriq 治疗三阴性乳腺癌即将获得FDA批准

2019-03-13

仁医06 (审核中...)

前往app查看评论内容

#PD-L1单抗#

欧洲药品管理局验证了默克PD-L1单抗Bavencio在晚期肾细胞癌中的疗效

2019-03-10

ylz8407 (审核中...)

前往app查看评论内容

#PD-L1单抗#

阿斯利康的PD-L1单抗Imfinzi欧洲获批用于治疗局部晚期且不可切除的非小细胞肺癌

2018-09-27

ylz8407 (审核中...)

前往app查看评论内容

#PD-L1单抗#

康宁杰瑞与思路迪联合开发的PD-L1单抗获国家食药总局临床批件

2017-01-08

ylz8407 (审核中...)

前往app查看评论内容

#PD-L1单抗#

罗氏的PD-L1单抗获优先审评权，有望今年9月获批上市

2016-03-23

ylz8407 (审核中...)

前往app查看评论内容

#PD-L1单抗#

Lancet：PD-L1单抗Atezolizumab治疗转移性尿路上皮癌活性和耐受性良好

2016-03-08

科室
- - 订阅+
  - 更多科室
工具
服务